Novartis closes Avidity deal as rare heart disease spinout launches
Lei Lei Wu / endpoints - Atrium Therapeutics launched Friday morning as Novartis closed the $12 billion deal to buy Avidity Biosciences and its RNA muscle therapies. The spinout will take on Avidity’s early-stage programs for genetic cardiomyopathies — heart muscle diseases ...
AI Summary: Novartis completed its Avidity Biosciences transaction and backed the launch of Atrium Therapeutics, a newly funded spinout focused on RNA therapies for rare cardiac conditions. Atrium inherits delivery platforms and early programs with substantial capital, as Novartis reshuffles assets to accelerate its RNA strategy — because apparently doubling down on hot modalities never gets old.
Warning: Undefined variable $thumbnail in /home3/thegood9/public_html/website_70aad9ea/cluster.php on line 61
Related Stories
Warning: Undefined variable $top_stories in /home3/thegood9/public_html/website_70aad9ea/cluster.php on line 128
Biogen announces $5.6B acquisition of Apellis Pharma / 1 month
Gilead buys Ouro Medicines for about $1.68–1.7B to bolster autoimmune pipeline / 2 months
Alfasigma pays $300M to GSK for linerixibat rights, expanding liver-disease portfolio / 2 months
Chiesi acquires KalVista for $1.9B to bolster rare disease pipeline / 29 days
Gilead acquires Tubulis in multibillion-dollar push beyond HIV / 7 wks
Eli Lilly buys Centessa for $6.3B to enter sleep disorder market / 2 months
StackHealth RSS
You can now follow topics by RSS - browse the complete list of topics, people, and organizations. Or, try Cybersecurity, Digital Health, Hearing Loss, Behavioral Health and look for the RSS link.
StackHealth Time Machine